Compile Data Set for Download or QSAR
Report error Found 56 Enz. Inhib. hit(s) with all data for entry = 12459
TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704116(US12138263, Compound 3A)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704123(US12138263, Compound 2B)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704124(US12138263, Compound 3B)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704122(US12138263, Compound 1B)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704119(US12138263, Compound 6A)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704120(US12138263, Compound 7A)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704118(US12138263, Compound 5A)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704163(US12138263, Compound 23C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704164(US12138263, Compound 24C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704161(US12138263, Compound 21C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704162(US12138263, Compound 22C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704159(US12138263, Compound 19C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704160(US12138263, Compound 20C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704157(US12138263, Compound 17C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704158(US12138263, Compound 18C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704169(US12138263, Compound 5D)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704168(US12138263, Compound 4D)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704165(US12138263, Compound 1D)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704166(US12138263, Compound 2D)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704147(US12138263, Compound 7C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704148(US12138263, Compound 8C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704145(US12138263, Compound 5C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704146(US12138263, Compound 6C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704143(US12138263, Compound 3C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704141(US12138263, Compound 1C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704142(US12138263, Compound 2C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704155(US12138263, Compound 15C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704156(US12138263, Compound 16C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704153(US12138263, Compound 13C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704154(US12138263, Compound 14C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704151(US12138263, Compound 11C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704152(US12138263, Compound 12C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704149(US12138263, Compound 9C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704150(US12138263, Compound 10C)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704129(US12138263, Compound 8B)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704125(US12138263, Compound 4B)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704139(US12138263, Compound 18B)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704137(US12138263, Compound 16B)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704135(US12138263, Compound 14B)
Affinity DataIC50: 1.00E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704144(US12138263, Compound 4C)
Affinity DataIC50: 5.50E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704126(US12138263, Compound 5B)
Affinity DataIC50: 5.50E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704140(US12138263, Compound 19B)
Affinity DataIC50: 5.50E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704138(US12138263, Compound 17B)
Affinity DataIC50: 5.50E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704167(US12138263, Compound 3D)
Affinity DataIC50: 5.50E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704136(US12138263, Compound 15B)
Affinity DataIC50: 5.50E+3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704115(US12138263, Compound 2A)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704131(US12138263, Compound 10B)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704132(US12138263, Compound 11B)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704114(US12138263, Compound 1A)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM704130(US12138263, Compound 9B)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (S12) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
US Patent

Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: